Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vapreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 0.80 |
| ▸ | SSTR5 known ✓ | P35346 | 15/20 | 0.80 |
| ▸ | SSTR3 known ✓ | P32745 | 8/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.78 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vapreotide SCHEMBL29384009 | 1.00 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29580907 | 1.00 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL30163296 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4826 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29405608 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4827 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL31632623 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL6369050 | 0.99 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL5200070 | 0.97 | SSTR2 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| SCHEMBL23482743 | 0.97 | SSTR5 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | claimed |
| EP-2136844-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | Centre De Recherche Sur Les Biotechnologies Marine (CA) | 2009-12-30 | — | — | EP | claimed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | claimed |
| EP-1773870-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | Novetide Ltd. (IL) | 2007-04-18 | — | — | EP | claimed |
| US-20060276626-A1 | Methods for the production of peptide derivatives | TEVA PHARMACEUTICALS USA, INC. | 2006-12-07 | — | — | US | claimed |
| WO-2006119388-A2 | METHODS FOR THE PRODUCTION OF PEPTIDE HAVING A C-TERMINAL AMIDE | NOVETIDE, LTD. (IL) | 2006-11-09 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-20040052855-A1 | Microparticles of biodegradable polymer encapsulating a biologically active substance and sustained release pharmaceutical formulations containing same | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1196148-B1 | PROCESS FOR MICROENCAPSULATION OF WATER SOLUBLE SUBSTANCES | DEBIO RECH PHARMA SA (CH) | 2003-12-17 | — | — | EP | disclosed |
| EP-1353648-A2 | MICROPARTICLES OF BIODEGRADABLE POLYMER ENCAPSULATING A BIOLOGICALLY ACTIVE SUBSTANCE | Debio Recherche Pharmaceutique S.A. (CH) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002058672-A2 | MICROPARTICLES OF BIODEGRADABLE POLYMER ENCAPSULATING A BIOLOGICALLY ACTIVE SUBSTANCE | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 2002-08-01 | — | — | WO | disclosed |
| EP-1196148-A1 | PROCESS FOR MICROENCAPSULATION OF WATER SOLUBLE SUBSTANCES | Debio Recherche Pharmaceutique S.A. (CH) | 2002-04-17 | — | — | EP | disclosed |
| WO-2000062761-A1 | PROCESS FOR MICROENCAPSULATION OF WATER SOLUBLE SUBSTANCES | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | SSTR2 2182/4885SSTR5 3634/4885SSTR3 2548/4885 |
| US-20060276626-A1 | Methods for the production of peptide derivatives | VIP, IAPP, PTMS | SSTR2 106/4885SSTR5 36/4885SSTR3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.